5-15% of DLBCL cases have been reported to carry MYC translocations [24] with concomitant high levels of MCT1 and MYC mRNA [16], highlighting that inhibition of MCT1 may represent a novel strategy to target MYC-dependent DLBCL. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.